Vanda Pharma (VNDA) Buy Rating and $15 PT Reiterated - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results
May 4, 2016 4:01 PM EDTWASHINGTON, May 4, 2016 /PRNewswire/ --Â Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2016.
"Vanda made significant progress in the first quarter of 2016," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "We continued to grow our HETLIOZ and Fanapt franchises and we look forward to a number of important clinical development milestones in the coming months."
Key Highlights:
Total net product sales from HETLIOZ® and Fanapt® were $33.3 million during the first quarter of 2016, a 4% increase... More